Printer Friendly

HPR Announces Largest Promotion Tracking Service Adding Urologists; MSA-Level Share-of Voice Activity Now Available on New Specialty Segment.

Health Products Research, Inc.(R) (HPR(R)) has added Urologists to its Metropolitan Area Promotional Audit (MPA) service -- the pharmaceutical industry's single source for monitoring sub-national field force promotional activities. Information on this new specialty segment will become available to clients in July 2003.

"Urologists are a critical segment of the physician population across several therapeutic areas, and will become a key focal point for many pharmaceutical companies over the forthcoming months, with anticipated product launches into the erectile dysfunction (ED) market as well as increased activities within the overactive bladder and BPH markets. Integrating this data will enable pharmaceutical companies to effectively assess and optimize share of voice and competitor impacts at a local level among this specialty group," added James Charnetski, Vice President of Market Research at HPR.

HPR has already recruited over 300 high prescribing Urologists, with plans on increasing this number to 400 by year-end. Sufficient representation will exist across the key MSA geographies of the U.S. The addition of Urologists increases HPR's comprehensive MPA physician database to over 15,000 physicians -- the largest of any syndicated promotional tracking service in the industry.

HPR, a division of Ventiv Health, Inc. , is located in Whitehouse, NJ. For questions or information on the Metropolitan Area Promotional Audit service, please contact Eileen Henne or Marc Rosner at (609) 771-9777.

About the MPA service:

The Metropolitan Area Promotional Audit (MPA) is a monthly service providing insights into pharmaceutical/healthcare company promotional activities and sales force structure across 22 metropolitan area geographies (MSA-GEOs). Physicians provide insights into the nature of the sales rep product discussions, the value of this information, their intent to prescribe the product, in addition to a host of other information collected on the sales rep call. This enables pharmaceutical companies to fine-tune their marketing & professional medical education support initiatives to better meet the on-going information needs of physicians and healthcare providers. The MPA service was launched in January 2000, and has a dedicated panel of over 15,000 physicians representing 12 specialty segments.

About HPR:

Headquartered in Whitehouse, NJ, Health Products Research has provided the pharmaceutical industry with sophisticated consulting services, including market research, promotion analyses, market segmentation, strategic planning, sales force deployment and call planning, for more than 30 years. Utilizing market, product and physician-level intelligence, in combination with advanced statistical modeling, mathematical techniques, and market research, HPR offers management solutions that maximize the effective use of promotional resources, optimizing Return on Investment (ROI).

About Ventiv Health

Ventiv Health, Inc. is a leading provider of comprehensive outsourced marketing and sales solutions for the pharmaceutical and life sciences industries. The Company works in consultative partnership with clients to identify strategic goals and develop customized, integrated solutions to optimize clients' product portfolios. Ventiv Health's market-leading offerings include: sales force recruitment, training and execution; consulting, analytics and forecasting; market research and intelligence; strategic and tactical planning and product and brand management.

For almost three decades, Ventiv Health has provided a broad range of innovative strategic and tactical solutions to clients including: Abbott Laboratories, Allergan, Altana, AstraZeneca, Aventis, Bayer, Bristol-Myers Squibb, Eli Lilly, Endo Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer and Schering-Plough. For more information on Ventiv Health, visit http://www.ventiv.com/.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

CONTACT: Investors - Corporate - John Emery of Ventiv Health, Inc., +1-732-537-4804, investor@ventiv.com; Client Questions - Marketing - Eileen Henne, ehenne@hprmrd.com or Marc Rosner, mrosner@hprmrd.com, both of Health Products Research, +1-609-771-9777

Web site: http://www.ventiv.com/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:4EUUK
Date:May 27, 2003
Words:698
Previous Article:The Sports Authority, Inc. Announces the 2002 Vendor of the Year Award Winners.
Next Article:Renovis Receives Milestone Payment From Astrazeneca As Phase III Trials Of Cerovive(R) (Nxy-059) Commence; Company Expands Management Team.
Topics:

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters